This article was originally published in The Tan Sheet
The U.S. Patent & Trademark Office (USPTO) has granted the request of an anonymous third party to reexamine Adams Respiratory Therapeutics' patent for the extended-release delivery technology in Mucinex. The tablets have a bi-layered design that provides immediate and extended guaifenesin release. The reexamination process could take up to three years, and during the interim the patent will remain in effect, Adams maintains. The patent extends through 2020, according to FDA's Orange Book. The 2002 Rx-to-OTC switch approval for Mucinex caused all single-ingredient extended-release Rx guaifenesin products to be withdrawn (1"The Tan Sheet" Oct. 21, 2002, p. 5)...
You may also be interested in...
Adams Respiratory Therapeutics expects its most recent patent on Mucinex brand OTC cough/cold remedies to protect the product line's market exclusivity until 2020, despite a challenge to an earlier patent on the products
Unapproved, single-ingredient guaifenesin extended-release Rx products should no longer be marketed because there is now an approved OTC version, according to FDA
Pfizer will aim to have its biosimilar Neulasta (pegfilgrastim) product, Nyvepria, on the market in both the EU and US by the end of the current quarter, a company spokesperson has informed Generics Bulletin, following a successful US launch.